144 related articles for article (PubMed ID: 38425632)
1. Rice Bran Arabinoxylan Compound and Quality of Life (RBAC-QoL) of Cancer Patients: An Interim Analysis of the RBAC-QoL Study.
Ooi SL; Micalos PS; Zielinski R; Pak SC
Cureus; 2024 Jan; 16(1):e53188. PubMed ID: 38425632
[TBL] [Abstract][Full Text] [Related]
2. Rice bran arabinoxylan compound and quality of life of cancer patients (RBAC-QoL): Study protocol for a randomized pilot feasibility trial.
Ooi SL; Pak SC; Micalos PS; Schupfer E; Zielinski R; Jeffries T; Harris G; Golombick T; McKinnon D
Contemp Clin Trials Commun; 2020 Sep; 19():100580. PubMed ID: 32548333
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular, endothelial function, and immune markers in response to treatment with a polysaccharide in HIV
Lewis JE; Atlas SE; Abbas MH; Rasul A; Farooqi A; Lantigua LA; Michaud F; Goldberg S; Lages LC; Gao J; Higuera OL; Fiallo A; Harvey PD; Tiozzo E; Woolger JM; Ciraula S; Mendez A; Rodriguez A; Konefal J
J Clin Transl Res; 2020 Apr; 5(3):140-147. PubMed ID: 32637718
[TBL] [Abstract][Full Text] [Related]
4. Modified Rice Bran Arabinoxylan by
Ooi SL; Micalos PS; Pak SC
Molecules; 2023 Aug; 28(17):. PubMed ID: 37687141
[TBL] [Abstract][Full Text] [Related]
5. Rice bran arabinoxylan compound as a natural product for cancer treatment - an evidence-based assessment of the effects and mechanisms.
Ooi SL; Micalos PS; Kim J; Pak SC
Pharm Biol; 2024 Dec; 62(1):367-393. PubMed ID: 38745507
[TBL] [Abstract][Full Text] [Related]
6. The Health-Promoting Properties and Clinical Applications of Rice Bran Arabinoxylan Modified with Shiitake Mushroom Enzyme-A Narrative Review.
Ooi SL; Pak SC; Micalos PS; Schupfer E; Lockley C; Park MH; Hwang SJ
Molecules; 2021 Apr; 26(9):. PubMed ID: 33925340
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Modified rice bran arabinoxylan as a nutraceutical in health and disease-A scoping review with bibliometric analysis.
Ooi SL; Micalos PS; Pak SC
PLoS One; 2023; 18(8):e0290314. PubMed ID: 37651416
[TBL] [Abstract][Full Text] [Related]
9. Changes in the Human Gut Microbiome during Dietary Supplementation with Modified Rice Bran Arabinoxylan Compound.
Schupfer E; Ooi SL; Jeffries TC; Wang S; Micalos PS; Pak SC
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513272
[TBL] [Abstract][Full Text] [Related]
10. RETRACTED ARTICLE: The Novel Effects of a Hydrolyzed Polysaccharide Dietary Supplement on Immune, Hepatic, and Renal Function in Adults with HIV in a Randomized, Double-Blind Placebo-Control Trial.
Lewis JE; Atlas SE; Abbas MH; Rasul A; Farooqi A; Lantigua LA; Michaud F; Goldberg S; Lages LC; Higuera OL; Fiallo A; Tiozzo E; Woolger JM; Ciraula S; Mendez A; Rodriguez A; Konefal J
J Diet Suppl; 2021; 18(2):I-XIII. PubMed ID: 30346850
[TBL] [Abstract][Full Text] [Related]
11. The Novel Effects of a Hydrolyzed Polysaccharide Dietary Supplement on Immune, Hepatic, and Renal Function in Adults with HIV in a Randomized, Double-Blind, Placebo-Control Trial.
Lewis JE; Atlas Bsn SE; Abbas MH; Rasul A; Farooqi A; Lantigua LA; Michaud F; Goldberg S; Lages LC; Higuera OL; Fiallo A; Tiozzo E; Woolger JM; Ciraula S; Mendez A; Rodriguez A; Konefal J
J Diet Suppl; 2020; 17(4):429-441. PubMed ID: 31146613
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Monk BJ; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Hurtado de Mendoza MO; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Martin Nguyen A; Monberg MJ; Colombo N; Lorusso D
Lancet Oncol; 2023 Apr; 24(4):392-402. PubMed ID: 36878237
[TBL] [Abstract][Full Text] [Related]
13. The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease.
Lewis JE; Atlas SE; Higuera OL; Fiallo A; Rasul A; Farooqi A; Kromo O; Lantigua LA; Tiozzo E; Woolger JM; Goldberg S; Mendez A; Rodriguez AE; Konefal J
Evid Based Complement Alternat Med; 2018; 2018():1751583. PubMed ID: 29853945
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
16. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
Coens C; Suciu S; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bottomley A; Kotapati S; de Pril V; Testori A; Eggermont AMM
Lancet Oncol; 2017 Mar; 18(3):393-403. PubMed ID: 28162999
[TBL] [Abstract][Full Text] [Related]
18. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.
Collins SE; Duncan MH; Saxon AJ; Taylor EM; Mayberry N; Merrill JO; Hoffmann GE; Clifasefi SL; Ries RK
Lancet Psychiatry; 2021 Apr; 8(4):287-300. PubMed ID: 33713622
[TBL] [Abstract][Full Text] [Related]
19. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
